Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma

Genes Chromosomes and Cancer

Volumn 51, Issue 5, 2012, Pages 462-472

  Iwakawa, Reika ^a   Okayama, Hirokazu ^a   Kohno, Takashi ^a   Sato Otsubo, Aiko ^b   Ogawa, Seishi ^b   Yokota, Jun ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; COPY NUMBER VARIATION; EXON; GENE; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GERM LINE; HEMIZYGOSITY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INTRON; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; MAJOR CLINICAL STUDY; PARK2 GENE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ADENOCARCINOMA; BASE SEQUENCE; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; GENE SILENCING; GENOTYPE; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84858000213     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21933     Document Type: Article

References (31)

1. Bradley WE, Di Paola D, Rampakakis E, Zannis-Hadjopoulos M. 2010a. More is less: Inactivation and deletion events and the search for tumor suppressor genes. J Cell Biochem 110: 281-287.
2. Bradley WE, Raelson JV, Dubois DY, Godin E, Fournier H, Privé C, Allard R, Pinchuk V, Lapalme M, Paulussen RJ, Belouchi A. 2010b. Hotspots of large rare deletions in the human genome. PLoS One 5: e9401.
3. Brüggemann N, Mitterer M, Lanthaler AJ, Djarmati A, Hagenah J, Wiegers K, Winkler S, Pawlack H, Lohnau T, Pramstaller PP, Klein C, Lohmann K. 2009. Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers. Parkinson Relat Disord 15: 425-429.
4. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100: 5956-5961.
5. Fogh J, Fogh JM, Orfeo T. 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221-226.
6. Iwakawa R, Kohno T, Enari M, Kiyono T, Yokota J. 2010. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci 101: 1891-1896.
7. Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M, Ogawa S, Yokota J. 2011. MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res 17: 1481-1489.
8. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. 2010. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 75: 1189-1194.
9. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adélaïde J, Geneix J, Xerri L, Dubreuil P, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Lopez M, Chaffanet M. 2007. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 26: 298-307.
10. Li X, Kitami T, Wang M, Mizuno Y, Hattori N. 2005. Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease. Parkinson Relat Disord 11: 485-491.
11. Lincoln SJ, Maraganore DM, Lesnick TG, Bounds R, de Andrade M, Bower JH, Hardy JA, Farrer MJ. 2003. Parkin variants in North American Parkinson's disease: Cases and controls. Mov Disord 18: 1306-1311.
12. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y. 1991. Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 100: 429-438.
13. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PI, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E, Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D. 2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 40: 1166-1174.
14. Mitsui J, Takahashi Y, Goto J, Tomiyama H, Ishikawa S, Yoshino H, Minami N, Smith DI, Lesage S, Aburatani H, Nishino I, Brice A, Hattori N, Tsuji S. 2010. Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet 87: 75-89.
15. Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M, Machida Y, Mochizuki H. 2008. Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 363: 2215-2227.
16. Morris LG, Veeriah S, Chan TA. 2010. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29: 3453-3464.
17. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071-6079.
18. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. 2010. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat 31: 763-780.
19. Park H, Kim JI, Ju YS, Gokcumen O, Mills RE, Kim S, Lee S, Suh D, Hong D, Kang HP, Yoo YJ, Shin JY, Kim HJ, Yavartanoo M, Chang YW, Ha JS, Chong W, Hwang GR, Darvishi K, Kim H, Yang SJ, Yang KS, Kim H, Hurles ME, Scherer SW, Carter NP, Tyler-Smith C, Lee C, Seo JS. 2010. Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing. Nat Genet 42: 400-405.
20. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA Jr, Carney D, Minna JD, Mulshine JL. 1996. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91.
21. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, Croce CM. 2004. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10: 2720-2724.
22. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. 2010. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 107: 15145-15150.
23. Rothenberg SM, Settleman J. 2010. Discovering tumor suppressor genes through genome-wide copy number analysis. Curr Genom 11: 297-310.
24. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA. 2010. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res 70: 2158-2164.
25. Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimizu K, Sekiguchi M, Terada M, Sugimura T. 1986. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci USA 83: 3997-4001.
26. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305.
27. Sobin LH, Wittekind CH, eds. 2002. TNM Classification of Malignant Tumors, 6th ed. New York: Wiley-Liss, pp. 99-103.
28. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. 2010. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42: 77-82.
29. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, Gazdar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. 1998. Genes Chromosomes Cancer 21: 308-319.
30. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, Koeffler HP, Ogawa S. 2007. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.
31. Zimprich A. 2011. Genetics of Parkinson's disease and essential tremor. Curr Opin Neurol 24: 318-323.